Thermo Fisher Launching New CDMO, CRO Services at CPHI Milan

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Thermo Fisher Scientific is launching Accelerator Drug Development, described as the company’s 360° contract development and manufacturing organization and contract research organization drug development solutions, as part of its showcase at CPHI Milan 2024, happening in Milan, Italy from Oct. 8–10, 2024. Thermo Fisher announced its exhibiting schedule in a press release on Oct. 7, 2024 (1).

According to the company, Accelerator Drug Development will impact the pharmaceutical value chain for biotech and large pharmaceutical companies with its customizable manufacturing, clinical research, and clinical supply chain services for small molecule, biologics, and cell and gene therapies (1). The services are intended to assist customers at every stage of the drug development lifecycle.

“Thermo Fisher is transforming drug development and manufacturing processes to support customers as they move critical programs forward to tackle global health challenges with speed, quality and efficiency,” said Michael Shafer, executive vice president and president, biopharma services, Thermo Fisher Scientific, in the press release. “We connect the steps between discovery and delivery—from early testing and analytical support to clinical research design to trial conduct, clinical supply chain management, manufacturing and commercial scale-up—and we strive to ensure a seamless transition, mitigate risks, and accelerate innovation at every stage.”

The launch of Accelerator Drug Development comes on the heels of a busy summer 2024 for Thermo Fisher, which in June opened a new building at its good manufacturing practice (GMP) facility in Middleton, Wis., then announced the completion of its acquisition of Olink Holding, a Sweden-based provider of next-generation proteomics solutions, in July (2–3). The company has also expanded sites in Cincinnati, Ohio, and Bend, Ore., to enhance R&D, manufacturing, and testing capabilities for oral solid dose drug formulations (1).

Thermo Fisher can be found at Booth 7B18 at CPHI Milan. Sessions at which its experts are scheduled to be contributors include:

• Navigating Shifts in CDMO-Pharma Relations: Trends and Implications, Faye Boeckman, senior director, market development, pharma services, Tuesday, Oct. 8, 11:35-12:30 CET, Hall 5 – 5B49
• Fireside Chat: Navigating Outsourcing Partnerships for Start-Ups, Kelly Howard, vice president, commercial operations, viral vector services global and advanced therapies, pharma services, Tuesday, Oct. 8, 13:15-13:40 CET, Hall 5 – 5B49
• Optimizing ADC Processes: Advanced Strategies with High-Quality Bioreagents, Dom Price, senior manager, technical sales, production chemicals and services–EMEA, bioproduction, Tuesday, Oct. 8, 13:45-14:10 CET, Hall 3 – 3F97
• Development and Validation of Automated Rapid Protocols to Ensure Mycoplasma-Free Biologics, Benjamin Ziehr, manager, cell lab, clinical research, Tuesday, Oct. 14:45-15:10 CET, Hall 5 – 5B49
• Maximizing Outsourcing and Manufacturing Success Through Strategic CDMO and CRO Partnerships, Jennifer Cannon, president, commercial operations, pharma services, Wednesday, Oct. 9, 13:45-14:10 CET, Hall 5 – 5B49 (1).

References

1. Thermo Fisher Scientific. Thermo Fisher Scientific Showcases Expanded Biopharma Services, Capabilities and Innovations at CPHI Milan 2024. Press Release. Oct. 7, 2024.
2. Thermo Fisher Scientific. Thermo Fisher Scientific Expands Clinical Research Laboratory in Wisconsin. Press Release. June 18, 2024.
3. Thermo Fisher Scientific. Thermo Fisher Scientific Completes Acquisition of Olink, Announces Commencement of Subsequent Offering Period. Press Release. July 10, 2024.